Literature DB >> 9886678

Transport of brain-derived neurotrophic factor across the blood-brain barrier.

W Pan1, W A Banks, M B Fasold, J Bluth, A J Kastin.   

Abstract

Brain-derived neurotrophic factor (BDNF) is a potential therapeutic agent for degenerative disorders of the central nervous system. In this report, we investigated the ability of BDNF to cross the blood-brain barrier (BBB). BDNF was stable in blood up to 60 min after i.v. injection, with evidence for aggregation, and had an early, rapid influx into brain. By 10 min, most of the BDNF sequestered by the cerebral cortex was associated with the parenchyma rather than with the endothelial cells, demonstrating complete passage across the BBB. A small dose of unlabeled BDNF enhanced the entry of 125I-BDNF from blood to brain after an i.v. bolus injection, whereas larger doses had no effect. In contrast, a large dose of unlabeled BDNF inhibited the influx of 125I-BDNF during in situ brain perfusion. After intracerebroventricular injection, the efflux of BDNF from brain to blood occurred at a rate similar to that for reabsorption of cerebrospinal fluid, and no evidence for self-inhibition was found. Therefore, we conclude that intact BDNF in the peripheral circulation crosses the BBB by a high-capacity, saturable transport system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886678     DOI: 10.1016/s0028-3908(98)00141-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  353 in total

1.  Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures.

Authors:  W C LaFrance; K Leaver; E G Stopa; G D Papandonatos; A S Blum
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

2.  Increased basal plasma brain-derived neurotrophic factor levels in sprint runners.

Authors:  Paulo Roberto Correia; Fulvio Alexandre Scorza; Sérgio Gomes da Silva; Aline Pansani; Michelle Toscano-Silva; Antonio Carlos de Almeida; Ricardo Mario Arida
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 3.  BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.

Authors:  J J Rakofsky; K J Ressler; B W Dunlop
Journal:  Mol Psychiatry       Date:  2011-09-20       Impact factor: 15.992

4.  Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.

Authors:  Shiou-Lan Chen; Sheng-Yu Lee; Yun-Hsuan Chang; Shih-Heng Chen; Chun-Hsieh Chu; Nian-Sheng Tzeng; I-Hui Lee; Po-See Chen; Tzung Lieh Yeh; San-Yuan Huang; Yen-Kuang Yang; Ru-Band Lu; Jau-Shyong Hong
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-23       Impact factor: 4.147

5.  [Molecular biological aspects of neuroplasticity: approaches for treating tinnitus and hearing disorders].

Authors:  B Mazurek; H Olze; H Haupt; B F Klapp; M Adli; J Gross; A J Szczepek
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

6.  Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models.

Authors:  Heath D Schmidt; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

7.  Association Between Objectively Measured Physical Activity and Plasma BDNF in Adolescents: DADOS Study.

Authors:  M R Beltran-Valls; M Adelantado-Renau; D Moliner-Urdiales
Journal:  J Mol Neurosci       Date:  2018-07-23       Impact factor: 3.444

8.  Caloric restriction improves memory in elderly humans.

Authors:  A V Witte; M Fobker; R Gellner; S Knecht; A Flöel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  Brain-derived neurotrophic factor Val66Met polymorphism and cognitive function in persons with cardiovascular disease.

Authors:  Ashley J Szabo; Michael L Alosco; Lindsay A Miller; John E McGeary; Athena Poppas; Ronald A Cohen; John Gunstad
Journal:  Psychogeriatrics       Date:  2013-10-28       Impact factor: 2.440

10.  Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.

Authors:  T Leyhe; Elke Stransky; G W Eschweiler; G Buchkremer; C Laske
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.